LineMatrix® Biological Vascular Graft for Infra-renal Arterial Bypass or Replacement

Sponsor
Shanghai Zhongshan Hospital
Study ID
NCT07733076
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Peripheral Arterial Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • LineMatrix® Biological Vascular Graft — DEVICE
    LineMatrix® Biological Vascular Graft for Infrarenal Arterial Bypass or Replacement

Study Details

Single center, single arm study to evaluate the Safety and Efficacy of LineMatrix® Biological Vascular Graft for Infra-renal Arterial Bypass or Replacement

Key Dates

First listed
Jul 29, 2026
Start date
Sep 30, 2026
Status verified
Jul 2026
Primary completion
Sep 30, 2027
Completion
Sep 30, 2028

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: LineMatrix® Biological Vascular Graft

Primary Outcome Measure

Primary patency rate at 6 months postoperatively [ Time Frame: 6 Months ]

Central Contacts

Related Studies